Lates News

AI quick news, Huaxin Securities released a research report on September 29th, giving a "buy" rating to Meihao Medical (301363.SZ). The reasons for the rating mainly include: 1) The cornerstone business is slightly under pressure, while new businesses are steadily progressing; 2) Mastering underlying technologies, strong horizontal migration capability of product categories, and the direction of brain-machine interface may become a new highlight. (Daily Economic News)